{"id":"W2592287337","doi":"10.1182/blood.v128.22.4194.4194","title":"Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; BC Cancer Agency; Jewish General Hospital","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; Internal medicine; Tolerability; Rituximab; Bendamustine; Follicular lymphoma; Oncology; Gastroenterology; Adverse effect; Lymphoma; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001472506,0.0009724058,0.00126689,0.0004032945,0.0003140135,0.0009298096,0.0007656573,0.0007015537,0.001808499],"category_scores_gemma":[0.0007076457,0.0005826082,0.0009541857,0.0004707721,0.0007222941,0.0008678223,0.0003334119,0.002250436,0.0005036051],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001078385,"about_ca_system_score_gemma":0.000890695,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008682333,"about_ca_topic_score_gemma":0.001816422,"domain_scores_codex":[0.999498,0.0002466076,0.00003798278,0.00008706093,0.00005070273,0.00007957665],"domain_scores_gemma":[0.9993758,0.0001233525,0.0001300217,0.00005560512,0.00003014368,0.0002852234],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6483306,0.103257,0.02455201,0.0007905728,0.002188019,0.000412445,0.0005008247,0.003254941,0.06110052,0.0001643652,0.002556925,0.1528917],"study_design_scores_gemma":[0.3224936,0.6323915,0.03332942,0.00003612258,0.0009991392,0.0004361316,0.00008853507,0.001758049,0.005810953,0.0001151677,0.002511177,0.00003012909],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972907,0.001032166,0.0001985039,0.000106922,0.00002739822,0.0004013527,0.0002554675,0.00003136773,0.0006561842],"genre_scores_gemma":[0.9971446,0.0006677381,0.0005015465,0.0001855185,0.00007341684,0.0003241021,0.000567837,0.00001023221,0.0005248819],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001808499,"threshold_uncertainty_score":0.007824242,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009850781726426483,"score_gpt":0.2395155685176439,"score_spread":0.2296647867912174,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}